Cyclooxygenase-2 Inhibition and Renal Function
Authors: Suzanne K. Swan, D. Craig Brater
Journal: Annals of Internal Medicine (2001)

Letters5 June 2001Cyclooxygenase-2 Inhibition and Renal FunctionSuzanne K. Swan, MD and D. Craig Brater, MDSuzanne K. Swan, MDHennepin County Medical Center; Minneapolis, MN 55404-1249 (Swan)Indiana University School of Medicine; Indianapolis, IN 46202-5114 (Brater)Search for more papers by this author and D. Craig Brater, MDHennepin County Medical Center; Minneapolis, MN 55404-1249 (Swan)Indiana University School of Medicine; Indianapolis, IN 46202-5114 (Brater)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-134-11-200106050-00019 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Substantial data have shown that both celecoxib and rofecoxib cause sodium retention similar to that caused by nonselective NSAIDs. We appreciate the reminder from Pfister and colleagues that other manifestations of sodium retention (such as pleural effusions) can also occur. The primary purpose of our study was to directly compare the peak effects of rofecoxib, indomethacin, and placebo on glomerular filtration rate and other variables of renal function in patients predisposed to such effects. The study that most similarly addresses the same question with celecoxib showed comparable effects (1). In that study, a single 400-mg dose of celecoxib ...References1. Rossat J, Maillard M, Nussberger J, Brunner HR, Burnier M. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther. 1999;66:76-84. [PMID: 0010430112] CrossrefMedlineGoogle Scholar2. Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, et al . Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther. 1999;289:735-41. [PMID: 0010215647] MedlineGoogle Scholar3. Geba GP, Weaver AL, Schnitzer TJ, et al . A clinical trial comparing rofecoxib to celecoxib and acetaminophen in the treatment of osteoarthritis (OA): early efficacy results [Abstract]. Ann Rheum Dis. 2000;59 Suppl 1 133. Google Scholar4. Perazella MA, Eras J. Are selective COX-2 inhibitors nephrotoxic? Am J Kidney Dis. 2000;35:937-40. [PMID: 0010793030] CrossrefMedlineGoogle Scholar5. Dunn MJ. Are COX-2 selective inhibitors nephrotoxic? Am J Kidney Dis. 2000;35:976-7. [PMID: 10793038] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Hennepin County Medical Center; Minneapolis, MN 55404-1249 (Swan)Indiana University School of Medicine; Indianapolis, IN 46202-5114 (Brater) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoEffect of Cyclooxygenase-2 Inhibition on Renal Function in Elderly Persons Receiving a Low-Salt Diet Suzanne K. Swan , David W. Rudy , Kenneth C. Lasseter , Charles F. Ryan , Kristin L. Buechel , Laurence J. Lambrecht , Manuel B. Pinto , Stacy C. Dilzer , Olga Obrda , Kimberly J. Sundblad , Carol P. Gumbs , David L. Ebel , Hui Quan , Patrick J. Larson , Jules I. Schwartz , Thomas A. Musliner , Barry J. Gertz , D. Craig Brater , and Siu-Long Yao Cyclooxygenase-2 Inhibition and Renal Function Alfred K. Pfister , Robert J. Crisalli , and William H. Carter Cyclooxygenase-2 Inhibition and Renal Function Andrew Whelton Metrics Cited ByThe therapeutic potential of NO-NSAIDsSelective cyclooxygenase-2 inhibitors: after the smoke has cleared 5 June 2001Volume 134, Issue 11Page: 1078KeywordsCyclooxygenase 2DrugsEffective doseGlomerular filtration rateHeart diseasesNSAIDsPleural effusionProspective studiesRenal failureSodium ePublished: 5 June 2001 Issue Published: 5 June 2001 CopyrightCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...